Crinetics Pharmaceuticals (CRNX) Preferred Shares Issued (2017 - 2018)
Crinetics Pharmaceuticals' quarterly Preferred Shares Issued came in at $9000.0 in Q4 2018, down 99.92% year-on-year from $12.0 million in Q4 2017, and up 103.85% quarter-over-quarter from -$234000.0 in Q2 2018.
Crinetics Pharmaceuticals has reported Preferred Shares Issued for 2 years, with the latest figure at $9000.0 in Q4 2018.
- For the quarter ending Q4 2018, Preferred Shares Issued fell 99.92% year-over-year to $9000.0; the trailing twelve-month figure through Dec 2018 stood at $63.3 million (changed N/A YoY), and the FY2018 full-year result was $63.3 million, up 427.29% from the prior year.
- Preferred Shares Issued for Q4 2018 stood at $9000.0, up from -$234000.0 in the prior quarter.
- The five-year high for Preferred Shares Issued was $63.5 million in Q1 2018, with the low at -$234000.0 in Q2 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 9,000.00 |
| Dec 31, 2018 | 9,000.00 |
| Jun 30, 2018 | -234,000.00 |
| Jun 30, 2018 | -234,000.00 |
| Mar 31, 2018 | 63.50 Mn |
| Mar 31, 2018 | 63.50 Mn |
| Dec 31, 2017 | 12.00 Mn |
| Dec 31, 2017 | 12.00 Mn |